HUTCHMED (NASDAQ:HCM) Announces Quarterly Earnings Results

HUTCHMED (NASDAQ:HCM) issued its quarterly earnings results on Thursday. The company reported $0.01 earnings per share for the quarter, reports. The business had revenue of $135.42 million during the quarter.

Here are the key takeaways from HUTCHMED’s conference call:

• FRUZAQLA delivered strong ex-China momentum with 26% growth and $366 million in in-market sales across >38 countries, providing a clear international growth driver despite U.S. Medicare Part D headwinds.
• China commercial sales recovered in H2 (21% H2 growth for ELUNATE), with NRDL renewal at no price cut and new indication/regulatory filings (RCC) supporting the company’s 2026 oncology revenue guidance of $330M–$450M.
• Balance sheet strength — roughly $1.4 billion cash — positions HUTCHMED to accelerate global development of its ATTC platform and pursue selective in‑licensing/M&A or partnerships to validate and scale the program.
• Pipeline catalysts ahead — two ATTC candidates (HMPL‑A251 and HMPL‑A580) are in global Phase I, A251 targets HER2‑expressing tumors with a reported bystander effect, and multiple near‑term readouts/NDA opportunities (SAFFRON, SANOVO, savolitinib gastric, Sovleplenib ITP) could materially re‑rate the story.
• Certain China products (ORPATHYS, Surufatinib) showed soft performance due to fierce competition and emerging PRRT/nuclear medicine entrants, and earlier China sales were pressured by salesforce restructuring after a GC indication setback — risks to near‑term commercial momentum remain.

HUTCHMED Price Performance

HCM remained flat at $13.85 on Friday. 3,718 shares of the company were exchanged, compared to its average volume of 38,408. HUTCHMED has a 12-month low of $11.51 and a 12-month high of $19.50. The company’s fifty day simple moving average is $14.71 and its 200 day simple moving average is $14.99. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65.

Institutional Investors Weigh In On HUTCHMED

Several large investors have recently made changes to their positions in HCM. Goldman Sachs Group Inc. lifted its holdings in shares of HUTCHMED by 8.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after acquiring an additional 7,342 shares in the last quarter. Jane Street Group LLC increased its holdings in HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after purchasing an additional 124,771 shares in the last quarter. M&G PLC raised its position in HUTCHMED by 0.4% in the second quarter. M&G PLC now owns 259,617 shares of the company’s stock valued at $3,894,000 after purchasing an additional 924 shares during the period. ABN Amro Investment Solutions acquired a new position in shares of HUTCHMED during the second quarter worth about $962,000. Finally, Tema Etfs LLC purchased a new stake in shares of HUTCHMED in the second quarter worth about $641,000. Institutional investors and hedge funds own 8.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on HCM shares. Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Weiss Ratings reiterated a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. Finally, Jefferies Financial Group upgraded shares of HUTCHMED to a “strong-buy” rating in a report on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, HUTCHMED currently has a consensus rating of “Hold” and a consensus price target of $20.88.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.